All In Biotech

Drug Trial Radar · NCT01519752

A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis

A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site, Study Comparing Oxiconazole Nitrate Cream 1% (Taro Pharmaceuticals,Inc) to Oxistat® (Oxiconazole Nitrate Cream) Cream 1% (PharmaDerma) in the Treatment of Tinea Pedis

Last checked: Nov 20, 2026Latest source record: Jan 22, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 661 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

661

Actual

Start

Nov 2011

Primary completion

Aug 2012

Study completion Nov 2012

Sponsor

Sponsor type
Industry
First posted
Jan 27, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to demonstrate that Oxiconazole nitrate 1% topical cream is effective for the treatment of patients with moderate to severe Tinea pedis.

Conditions

  • Tinea Pedis

Interventions

  • Oxiconazole Nitrate Cream 1%Drug

    Oxiconazole Nitrate Cream 1% applied to affected area once a day for 28 days

  • Oxiconazole Nitrate Cream 1% (Oxistat®)Drug

    Oxiconazole Nitrate Cream 1%(Oxistat®)applied to affected area once a day for 28 days

  • PlaceboDrug

    Placebo applied to affected area once a day for 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Therapeutic CureTime frame: Day 42

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.